Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 3/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022839 | 0.97 | CTSS (0.49) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL1022989 | 0.92 | CTSS (0.54) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL1021128 | 0.85 | SIRT5 (0.45) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL13198524 | 0.85 | ATM (0.55) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL15238968 | 0.84 | CTSK (0.53) | CTSSCTSLCTSBCTSKFOLH1 | |
| SCHEMBL15238846 | 0.83 | CTSK (0.57) | CTSLCTSBCTSK | |
| SCHEMBL1022566 | 0.82 | CTSK (0.48) | CTSSCTSLCTSBCTSKAKT1 | |
| SCHEMBL28820385 | 0.82 | L3MBTL1 (0.42) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL15238498 | 0.82 | L3MBTL1 (0.42) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL15238875 | 0.81 | ATM (0.51) | CTSSCTSLCTSBATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-09-11 | — | — | US | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| US-9512109-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | disclosed |
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CTSS 3615/4885CTSL 1390/4885CTSB 2938/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CTSS 3597/4885CTSL 1433/4885CTSB 2879/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CTSS 3615/4885CTSL 1390/4885CTSB 2938/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CTSS 3615/4885CTSL 1390/4885CTSB 2938/4885 |
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | CTSS 2/4885CTSL 12/4885CTSB 5/4885 |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CTSS 3615/4885CTSL 1390/4885CTSB 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.